{"name":"Dart NeuroScience, LLC","slug":"dart-neuroscience-llc","ticker":"","exchange":"","domain":"","description":"Dart NeuroScience, LLC is a biotechnology company focused on the discovery and development of novel therapeutics for neurodegenerative diseases. Despite having several drug candidates in earlier stages of development, the company has faced challenges with discontinuing some of its programs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BLX-028914","genericName":"BLX-028914","slug":"blx-028914","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"BLX-028914","genericName":"BLX-028914","slug":"blx-028914","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxQR0w1ejJpR1N2dzhCbWZXWlZWak9BM09iSkpFWV8xbi0wYTUxNHpOMlBHc3pZNzZuTXVuTHhVQjlwbXUxMnNWVi0wcUpOUnhINkRNMXUtcF9sT3ByWUxlamE1R2VVdW5DMHROOUNwRjhDZ3hPUk1Jc0w5bXA4Qm5McVZJTklFaEJfYlF6eWhCZS12WVJYZks3RnFTVWNwRzdQWklLaWN6ZFJXS3NPQzVyN09hbEYzV1Fsc0hKQTd2bEdEeXhpU1pzN19pVGQ2c3lpM1I4NzR1SHpGZ3hYWF90VmxtaEdSajhRV0tqdjBiOURDcFA3VHU5MUtJaEp4dnJYTjJPaVUzbGZ6VGctQk1tcTg4N3NtTWN5ODhwbTNtSnoxaGJQdkdxa2NsOXBEZw?oc=5","date":"2026-01-12","type":"trial","source":"BioSpace","summary":"Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals - BioSpace","headline":"Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Synd","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-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?oc=5","date":"2012-04-09","type":"pipeline","source":"Newswise","summary":"NYU School of Medicine Presents Three Biomedical Researchers 2012 DART/NYU Biotechnology Achievement Awards for Role of Pure Science | Newswise - Newswise","headline":"NYU School of Medicine Presents Three Biomedical Researchers 2012 DART/NYU Biotechnology Achievement Awards for Role of ","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}